dapsone / Generic mfg. - LARVOL DELTA

HYPOXIA MYSTERY: UNRAVELING DAPSONE-INDUCED METHEMOGLOBINEMIA IN A SUSPECTED COVID-19 PNEUMONIA (CHEST 2025) - No abstract available

Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pneumonia

DAPSONE-INDUCED METHEMOGLOBINEMIA MIMICKING RECURRENT PNEUMOCYSTIS PNEUMONIA IN AN HIV PATIENT ON PCP PROPHYLAXIS: DIAGNOSTIC AND MANAGEMENT CHALLENGES (CHEST 2025) - No abstract available

Clinical • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Pneumonia • Respiratory Diseases

FEELING BLUE: A CASE OF DAPSONE-INDUCED METHEMOGLOBINEMIA (CHEST 2025) - No abstract available

Clinical • Hematological Disorders

DAPSONE-INDUCED HYPERSENSITIVITY PNEUMONITIS IN A PATIENT WITH HANSEN'S DISEASE (CHEST 2025) - No abstract available

Clinical • Immunology • Inflammation • Pneumonia • Pulmonary Disease

DAPSONE-RELATED METHEMOGLOBINEMIA TREATED WITH HIGH-DOSE ASCORBIC ACID IN A LUNG TRANSPLANT RECIPIENT (CHEST 2025) - No abstract available

Clinical • Hematological Disorders • Transplantation

SECOND-LINE THERAPEUTIC OPTIONS IN MANAGEMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA : REAL-WORD EXPERIENCE OF 237 PATIENTS (EHA 2025) - "Splenectomy is a gold standard for treatment in chronic ITP in our country but increase the risk of septicemia, coronary disease and thrombotic events; however emergence of new drugs has modified ITP management.Drug accessibility and other factors related to the choice of second-line therapies require further evaluation."

Clinical • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Ischemic stroke • Thrombocytopenia • Thrombocytopenic Purpura

Lucio's Phenomenon in a Non-Endemic Region: A Case Report (CDA 2025) - "The patient was treated with a 24-month multi-drug therapy regimen, including clofazimine, rifampin, dapsone, and prednisone. In conjunction with Infectious Diseases and a positive PCR result for Mycobacterium leprae , we were able to arrive at the correct diagnosis. However, mycobacterial infections, such as leprosy, can present with clinical signs and laboratory findings suggestive of autoimmune rheumatologic diseases, posing significant diagnostic challenges.The infection was likely misdiagnosed multiple times due to the rarity of leprosy in non-endemic regions, demonstrating the critical role of a multidisciplinary approach in the accurate diagnosis and treatment of this infection."

Case report • Clinical • ANCA Vasculitis • Cardiovascular • Dermatitis • Dermatology • Endocrine Disorders • Hematological Disorders • Immunology • Infectious Disease • Rheumatology • Vasculitis

TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity. (PubMed, Signal Transduct Target Ther) - "Using dapsone hypersensitivity syndrome (DHS) as a paradigm for SCARs, we show that the DHS patients harbor a sex-related global reduction in blood NK cells, contributing to the higher incidence of reactions in females...These results demonstrate that TSC22D3-regulated NK cells play a critical role in predisposing to drug hypersensitivity reactions, bridging innate and adaptive immune dysregulation in SCARs pathogenesis. Our study highlights the importance of NK cell heterogeneity and TSC22D3 in immune-mediated hypersensitivity disorders, offering potential therapeutic targets for SCARs and related conditions."

Journal • Immunology • CD4 • CD8 • IL15 • TSC22D3

Severe Treatment-Resistant Methemoglobinemia of Unknown Etiology With Recurrence. (PubMed, Case Rep Crit Care) - "This was again thought secondary to dapsone, given the long half-life of dapsone and potential for enterohepatic recirculation...Suggestion was that azathioprine could be the causative agent; however, this has not been reported previously...This case highlights the potential for refractory methemoglobinemia requiring repeated treatment, and the importance of longer periods of close observation. It is important to consider the diagnosis in patients without a clear trigger for methemoglobinemia, as an identifiable cause may not always be clear."

Journal • Critical care • Hematological Disorders

Molecular Detection of Gene Mutation Related to Drug Resistance in Mycobacterium leprae. (PubMed, Int J Mycobacteriol) - "The study identified mutations in the gyrA gene which is associated with ofloxacin resistance in M. leprae in Central India. While the absence of resistance to first-line anti-leprosy drugs is reassuring, the emergence of resistance to fluoroquinolones is a cause for concern. Early detection of resistant strains facilitates prompt initiation of drug therapies, reducing their spread and advancing the global leprosy eradication effort."

Journal

Successful treatment of refractory pyoderma gangrenosum with risankizumab in a 57-year-old patient: A case report. (PubMed, SAGE Open Med Case Rep) - "Initial treatments, including topical therapies (high-potency steroids, dapsone, and calcineurin inhibitors) and conventional systemic immunosuppressive therapies (corticosteroids and tumor necrosis factor inhibitors), failed to produce significant improvement. However, treatment with risankizumab, an interleukin-23 inhibitor, resulted in substantial ulcer healing over a few weeks and ultimately led to complete resolution."

Journal • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Pain • Pyoderma Gangrenosum • Rheumatoid Arthritis • Rheumatology

Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report. (PubMed, SAGE Open Med Case Rep) - "Despite multiple failed therapies, including methotrexate, dapsone, acitretin, and naltrexone, she showed rapid improvement within 2 weeks of abrocitinib (100 mg daily), a JAK1 inhibitor, with sustained control at 2 months follow-up. This case adds to growing evidence that JAK inhibitors, particularly abrocitinib, may serve as an effective targeted therapy for refractory Hailey-Hailey disease. Further clinical trials are needed to confirm its long-term efficacy and safety."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Genetic Disorders • Immunology • Inflammation • Pain • IL13 • IL4

Epidermolysis Bullosa Acquisita: A Rare Pediatric Presentation of a Rare Blistering Disorder (CDA 2025) - "Colchicine and intermittent courses of prednisone improved his mucocutaneous blistering for three years, however at age 11, he was re-referred to Dermatology due to worsening blistering. Differentiating EBA from EB is critical, as there is a role for initiating immunomodulatory or immunosuppressive therapy in cases of EBA. Systemic corticosteroids and dapsone—which our patient responded well to—are frequently treatments of choice for pediatric EBA, while colchicine has shown some benefit in adult EBA."

Clinical • Dermatology • Developmental Disorders • Hematological Disorders • Inflammation • Pediatrics • Thrombocytopenia

Linear IgA/IgG bullous dermatosis associated with linagliptin: a case report (CDA 2025) - "The linagliptin was replaced with metformin, and he was treated with prednisone, dapsone and topical corticosteroids, with a slow improvement. LAGBD is a rare subtype of bullous pemphigoid that may also be triggered by the gliptin class of antidiabetic medication. The condition can persist despite discontinuation of the offending drug but usually responds well to dapsone or immune suppressants like mycophenolate mofetil."

Case report • Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Pruritus

Lupus miliaris disseminatus faciei: A rare facial granulomatous disorder (CDA 2025) - "Variable improvement has been reported with systemic steroids, isotretinoin, dapsone, tetracycline or nitroimidazole-based antibiotics, antimalarials, antituberculosis therapy, tranilast, apremilast, tacrolimus, cyclosporine, and JAK inhibitors...Although doxycycline treatment failed, the patient improved with a tapering prednisone course and isotretinoin 60 mg daily...While it often resolves spontaneously, early intervention is crucial to minimize cosmetic and psychological impacts. The variable efficacy of treatments highlights the need for tailored therapeutic approaches."

Aesthetic Medicine • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Respiratory Diseases • Rosacea • Sarcoidosis • Tuberculosis

An unusual case of erythema elevatum diutinum (CDA 2025) - "Treatment with a super-potent topical corticosteroid and topical dapsone were ineffective and oral dapsone was not tolerated. Intralesional triamcinolone acetonide 5-10 mg /ml resulted in transient improvement...CONCLUSIONS Chronic recurrent LCV may be an early solitary presenting feature of EED. This presentation alters how EED may be defined and widens the differential diagnosis of palpable purpura to include EED as a possible consideration."

Clinical • Dermatology • Vasculitis

Differences in clinical presentation between drug-induced and non-drug-induced linear IgA bullous dermatosis: a systematic review (CDA 2025) - "Dapsone and systemic corticosteroids were the most frequently used treatments for both subtypes, in addition to drug discontinuation when a medication was identified as the triggering factor. Strong association with specific medications, particularly vancomycin, underscores the importance of prompt recognition and management, with drug discontinuation playing a critical role in treatment. Further research is needed to elucidate the underlying pathophysiology driving these clinical differences."

Clinical • Review • Dermatology • Immunology

Ustekinumab in the management of pyoderma gangrenosum: A single-centre case series (CDA 2025) - "All patients failed topical corticosteroid therapy and at least one systemic therapy (e.g., prednisone, dapsone, colchicine) prior to initiating ustekinumab. Critically, patient adherence and concurrent management played a significant role in outcomes. Larger prospective studies are needed to evaluate ustekinumab efficacy, safety, and optimal dosing in PG management."

Clinical • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pyoderma Gangrenosum • Ulcerative Colitis

Treatment Algorithm Suggestion for Hailey-Hailey Disease. (PubMed, J Cutan Med Surg) - "Treatments include topical agents (corticosteroids, calcineurin inhibitors, antibiotics, calcitriol) and systemic agents (antibiotics, anticholinergics, retinoids, apremilast, dapsone, immunosuppressants, biologicals, naltrexone, vitamin D), as well as procedural therapy such as carbon dioxide laser, botulinum toxin, dermabrasion, photodynamic therapy, and surgery. This review presents a systematic analysis of the literature with a focus on both established and emerging treatment options for Hailey-Hailey disease with the aim to provide a therapeutic algorithm. The evidence supporting each treatment option will be assessed, emphasizing the strength of the data to guide clinical decision-making."

Journal • Review • Dermatology • Genetic Disorders

URTICARIAL VASCULITIS: REGISTRY OF 21 CASES (EULAR 2025) - "Omalizumab was administered in 3 cases (14.3%); cyclophosphamide in 1 case; and rituximab in another. None received dapsone or colchicine... Urticarial vasculitis is a rare disease that usually presents with predominantly cutaneous involvement. It manifests with urticarial lesions lasting more than 24 hours. Etiological search or association with autoimmune diseases, infections, neoplasms, and drugs should be highlighted."

Clinical • Cardiovascular • Complement-mediated Rare Disorders • Dermatology • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Infectious Disease • Musculoskeletal Pain • Oncology • Pain • Rare Diseases • Rheumatology • Sjogren's Syndrome • Urticaria • Vasculitis

REGISTRY OF ANIFROLUMAB USE IN SYSTEMIC LUPUS ERYTHEMATOSUS IN THE VALENCIAN COMMUNITY (EULAR 2025) - "Only 1 patient was treated with anifrolumab without prior disease-modifying antirheumatic drugs (DMARDs) therapy, with an average of 2.6±1.25 previous DMARDs (23 hydroxychloroquine, 13 MTX, 15 azathioprine, 10 mycophenolate, 5 tacrolimus, 5 leflunomide, 1 cyclosporine, 1 chloroquine, 1 dapsone). The mean number of prior biologics before starting Anifrolumab was 1.29±0.78 (15 belimumab, 13 rituximab, 1 tocilizumab, 1 abatacept, 2 antiTNF, 1 cenerimod). Only 33.33% required corticosteroid boluses, and one required cyclophosphamide. Anifrolumab was concomitantly prescribed with hydroxychloroquine in 53.33% of patients, mycophenolate in 13.33%, methotrexate in 20% and azathioprine, tacrolimus and mepacrine in 6.66%... From the third month of Anifrolumab treatment, a significant reduction in prednisone dose mantained until 6th month, as well as SLEDAI scores, were observed. The domains showing the greatest improvement were hematological, joint, and mucocutaneous,..."

Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Efficacy and safety of treatment with dapsone in patients with pediatric IgA vasculitis refractory to conventional treatment (EULAR 2025) - "Dapsone treatment was highly effective in all patients, rapidly controlling several moderately severe clinical domains."

Clinical • Gastroenterology • Hematological Disorders • Inflammation • Pain • Pediatrics • Renal Disease • Rheumatology • Vasculitis

Association of Treating Strategy Adjustment for IgG4-RD Relapse and Recurrent Relapse: Lessons from a Prospective Cohort (EULAR 2025) - "For GC adjustment strategy, the use of one dose of dapsone is permitted in the “unchanged oral prednisone” group. When treating relapse in IgG4-RD, regimens including GCs were more likely to prevent recurrent relapses, especially for the patients with internal organ involvement."

Clinical • Inflammation

The Dapsone Conundrum: Understanding Implications of Adverse Reactions to Dapsone Including Dapsone Hypersensitivity Syndrome in Leprosy Patients Treated With Multidrug Therapy. (PubMed, Int J Dermatol) - "While dapsone remains a cornerstone in the treatment of leprosy, the potential for clinically significant though infrequent adverse reactions highlights the need for vigilant monitoring and increased awareness among healthcare providers of the diverse manifestations of dapsone-related side effects."

Journal • Dermatology • Hematological Disorders • Immunology • Psychiatry

Unravelling VEXAS syndrome: shedding light on a recently recognised medical condition. (PubMed, BMJ Case Rep) - "Treatment challenges persisted, with dapsone, mycophenolate mofetil and corticosteroids showing limited efficacy. Tocilizumab, guided by multidisciplinary collaboration and genetic sequencing, yielded positive results, emphasising its promising role...However, individually tailored approaches and continued research will lead to improved outcomes. This case report underscores the importance of interdisciplinary collaboration, heightened awareness and personalised strategies in managing VEXAS syndrome."

Journal • Dermatology • Hematological Disorders • Hematological Malignancies • Immunology • Musculoskeletal Diseases • Myelodysplastic Syndrome • Oncology • Urticaria • Vasculitis